Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

enGene Holdings Inc. - Common Stock (NQ:ENGN)

6.205 +0.235 (+3.94%)
Streaming Delayed Price Updated: 1:56 PM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 99,300
Open 6.080
Bid (Size) 6.130 (1)
Ask (Size) 6.280 (3)
Prev. Close 5.970
Today's Range 5.929 - 6.350
52wk Range 2.650 - 11.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
enGene Holdings Inc (NASDAQ:ENGN) Posts Wider-Than-Expected Q3 Loss as R&D Spending Doubles
enGene posts wider-than-expected Q3 loss as R&D spending doubles. The biotech advances its pivotal LEGEND trial and secures key FDA RMAT designation. 
Via Chartmill
enGene Posts 78% Expense Jump in Q3
Via The Motley Fool

Performance

YTD
-12.1%
-12.1%
1 Month
+66.8%
+66.8%
3 Month
+87.5%
+87.5%
6 Month
+21.0%
+21.0%
1 Year
-8.6%
-8.6%

More News

Read More
enGene Reports Third Quarter 2025 Financial Results and Provides Business Update
From enGene Holdings Inc.
Via Business Wire
enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort
From enGene Holdings Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
enGene to Participate in Upcoming Investor Conferences
From enGene Holdings Inc.
Via Business Wire
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
enGene Announces Board and Leadership Appointments to Support Commercial Readiness
From enGene Holdings Inc.
Via Business Wire
FDA Grants RMAT Designation for enGene’s Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer
From enGene Holdings Inc.
Via Business Wire
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
enGene Reports Second Quarter 2025 Financial Results and Provides Business Update
From enGene Holdings Inc.
Via Business Wire
enGene Announces the Resignation of its Chief Medical Officer
From enGene Holdings Inc.
Via Business Wire
enGene to Present at the Jefferies Global Healthcare Conference
From enGene Holdings Inc.
Via Business Wire
enGene Names Amy Pott as Chief Global Commercialization Officer
From enGene Holdings Inc.
Via Business Wire
enGene to Participate in Upcoming Investor Conferences
From enGene Holdings Inc.
Via Business Wire
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum
From enGene Holdings Inc.
Via Business Wire
enGene Reports First Quarter 2025 Financial Results and Provides Business Update
From enGene Holdings Inc.
Via Business Wire
enGene to Participate in the Leerink Partners Global Healthcare Conference
From enGene Holdings Inc.
Via Business Wire
This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From enGene Holdings Inc.
Via Business Wire
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)
From enGene Holdings Inc.
Via Business Wire
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
enGene Reports Full Year 2024 Financial Results and Provides a Business Update
From enGene Holdings Inc.
Via Business Wire

Frequently Asked Questions

Is enGene Holdings Inc. - Common Stock publicly traded?
Yes, enGene Holdings Inc. - Common Stock is publicly traded.
What exchange does enGene Holdings Inc. - Common Stock trade on?
enGene Holdings Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for enGene Holdings Inc. - Common Stock?
The ticker symbol for enGene Holdings Inc. - Common Stock is ENGN on the Nasdaq Stock Market
What is the current price of enGene Holdings Inc. - Common Stock?
The current price of enGene Holdings Inc. - Common Stock is 6.205
When was enGene Holdings Inc. - Common Stock last traded?
The last trade of enGene Holdings Inc. - Common Stock was at 09/16/25 01:56 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.